Neurocrine BiosciencesNBIX
Market Cap: $12.1B
About: Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
Employees: 1,500
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
134% more call options, than puts
Call options by funds: $125M | Put options by funds: $53.6M
34% more repeat investments, than reductions
Existing positions increased: 249 | Existing positions reduced: 186
7% more first-time investments, than exits
New positions opened: 78 | Existing positions closed: 73
1% more funds holding
Funds holding: 576 [Q1] → 581 (+5) [Q2]
2% less capital invested
Capital invested by funds: $13.1B [Q1] → $12.9B (-$207M) [Q2]
2.4% less ownership
Funds ownership: 95.47% [Q1] → 93.07% (-2.4%) [Q2]
11% less funds holding in top 10
Funds holding in top 10: 9 [Q1] → 8 (-1) [Q2]
Research analyst outlook
18 Wall Street Analysts provided 1 year price targets over the past 3 months
18 analyst ratings
Cantor Fitzgerald Charles Duncan 47% 1-year accuracy 32 / 68 met price target | 29%upside $155 | Overweight Maintained | 29 Aug 2024 |
RBC Capital Brian Abrahams 52% 1-year accuracy 39 / 75 met price target | 13%upside $136 | Sector Perform Maintained | 29 Aug 2024 |
HC Wainwright & Co. Andrew Fein 46% 1-year accuracy 77 / 166 met price target | 58%upside $190 | Buy Reiterated | 29 Aug 2024 |
Piper Sandler David Amsellem 61% 1-year accuracy 22 / 36 met price target | 32%upside $159 | Overweight Upgraded | 29 Aug 2024 |
BMO Capital Evan Seigerman 69% 1-year accuracy 9 / 13 met price target | 7%upside $128 | Market Perform Maintained | 29 Aug 2024 |
Financial journalist opinion
Based on 11 articles about NBIX published over the past 30 days